Data as of Dec 04
| -0.02 / -1.59%|
Cleveland BioLabs, Inc. is a clinical-stage biotechnology company leveraging deep mechanistic understanding of the cell death process, apoptosis, to develop a robust pipeline of compounds primarily focused on oncology applications and mitigation of radiation injury. The company's lead compound is being developed as both a radiation countermeasure and a cancer treatment. Its pipeline includes products from two primary families of compounds: Protectans, which are being developed as drug candidates that protect normal tissues from acute stresses, such as radiation, chemotherapy and ischemias; and Curaxins, which are being developed as anticancer agents that could act as mono-therapy drugs or in combination with other existing anticancer therapies. The company was founded by Andrei V. Gudkov on June 5, 2003 and is headquartered in Buffalo, NY.
|Yakov Kogan||Chief Executive Officer, COO & Director|
|C. Neil Lyons||CFO, Head-Investor & Public Relations|
|Andrei V. Gudkov||Director & Chief Scientific Officer|
|Michael R. Kurman||Chief Medical Officer|
|Michael Paterno||Director-Clinical Operations|